Vor Biopharma Inc.
Most recent annual filing: 2026-03-15
Pipeline (4 active programs)
Discontinued (4)
- tremtelectogene empogeditemcel — Acute Myeloid Leukemia · winddown of prior clinical and manufacturing operations announced May 8, 2025; IP sold in August/September 2025
- tremtelectogene empogeditemcel — Myelodysplastic Syndrome · winddown of prior clinical and manufacturing operations announced May 8, 2025; IP sold in August/September 2025
- VCAR33 — Acute Myeloid Leukemia · winddown of prior clinical and manufacturing operations announced May 8, 2025; IP sold in August/September 2025
- VADC45 — undisclosed · winddown of prior clinical and manufacturing operations; IP sold in August/September 2025
Biotech Distilled coverage (3)
- 2026-05-15 UPDATE: Vor Bio (VOR) - NEJM Stamps the Free Look 🔒 Paid
- 2026-04-27 UPDATE: Vor Bio (VOR) - The Anchor is Selling 🔒 Paid
- 2026-04-06 Vor Bio (VOR) - Scientific Deep Dive Fortelitacicept and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.